Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.70 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.70 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.70 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.70 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.54 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.54 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.54 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.54 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.54 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | BACE1 | P56817 | 1/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188244 | 0.98 | ADRA2A (0.73) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| Hydrochloric Acid SCHEMBL2364489 | 0.95 | BLM (0.74) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| Bromide SCHEMBL916427 | 0.93 | SLC6A2 (0.67) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL11709558 | 0.91 | ADRA2A (0.64) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL940013 | 0.91 | SLC6A2 (0.70) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL4860354 | 0.88 | ADRA2A (0.67) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL29239961 | 0.88 | ADRA2A (0.67) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL28381835 | 0.88 | ADRA2A (0.67) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL11271713 | 0.88 | ADRA2A (0.67) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL8443488 | 0.88 | ADRA2A (0.67) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368450-B2 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | PARION SCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1485359-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7247636-B2 | Phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7241766-B2 | Methods of using phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7192959-B2 | Antihistamines; antiinflammatory agents; bronchodilator agents; inflammatory bowel disorders; psoriasis | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192958-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1485359-A4 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6858614-B2 | Phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1485359-A2 | SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040204424-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | PARION SCIENCES, INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040198745-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040198746-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040198744-A1 | Methods of using phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20030195160-A1 | Sodium channel blockers | CYFI, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003070184-A2 | SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204424-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | CFTR, TRPC4, TRPC5 | ADRA2A 342/4885SLC6A2 418/4885HTR1A 782/4885 |
| US-20030195160-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ADRA2A 213/4885SLC6A2 105/4885HTR1A 617/4885 |
| US-20040198745-A1 | Sodium channel blockers | SCN2B, SCN4A, SCN1B | ADRA2A 160/4885SLC6A2 215/4885HTR1A 444/4885 |
| US-20040198744-A1 | Methods of using phenolic guanidine sodium channel blockers | KCNH2, KCNH3, KCNJ1 | ADRA2A 168/4885SLC6A2 61/4885HTR1A 374/4885 |
| US-20040198746-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ADRA2A 213/4885SLC6A2 105/4885HTR1A 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.